Selank research at Deep Dive Peptides

Selank’s anxiety reputation leads into several different places: rat frontal cortex, hippocampus, stressed behavior and human blood. The immune findings make the anxiety reputation less simple than it first seems.

The Selank research compound

Selank, also called TP-7, is a synthetic seven-amino-acid peptide derived from tuftsin, a natural immune-signaling fragment. The added Pro-Gly-Pro end was intended to slow degradation. The molecular review discusses how its anxiety-related activity may involve GABA receptor binding, alongside other mechanisms.

I suspect that calling it a “calming peptide” loses something important about its immune origin. Anxiety was a development aim, but the molecule’s biological questions extend beyond how calm an animal behaves. Russia registers Selank as a prescription anxiolytic for anxiety with exhaustion. Neither the FDA nor the EMA has approved it. Research-labelled supplies are intended for laboratory work.

Selank mechanism of action in the frontal cortex

GABA is a chemical messenger that helps quiet nerve signaling. In the rat-brain membrane work discussed by the 2018 review, Selank increased GABA binding in a concentration-dependent and subtype-selective way. The review describes modulation distinct from familiar benzodiazepines. That is a tissue-binding finding.

The 2016 frontal-cortex experiment in rats examined gene expression instead. Selank changed the expression of 45 genes at 1 hour and 22 genes at 3 hours. Its pattern correlated positively with changes produced by GABA itself. I’d follow that correlation into the GABA system, with the behavioral consequences still requiring their own measurements.

The counts below describe how many genes changed at each time. A smaller count later says nothing by itself about the size of the remaining changes or how anxious a rat felt.

Two horizontal bars show 45 changed genes at 1 hour and 22 at 3 hours in rat frontal cortex — Selank and rat frontal-cortex gene expression. Counts at separate time points from Volkova and colleagues; these are neither patient counts nor anxiety scores.

Selank BDNF research in the hippocampus

The 2008 intranasal Selank paper reported increased BDNF expression in the rat hippocampus. BDNF supports nerve-cell survival and plasticity. The reported increase concerned copies of the instructions for that protein in that region.

I’m tempted by the hippocampus connection, too. The measured outcome here remains a molecular change in rat hippocampus. It leaves human memory performance and the consequences of repeated exposure unresolved. The Semax page has related neurotrophin findings, including a separate measurement of finished BDNF protein.

Diazepam and stressed rats

In the 2017 unpredictable chronic mild stress experiment, Selank combined with diazepam reduced anxiety-like behavior more effectively than either alone and moved behavior toward pre-stress levels. The subjects were rats.

I regard that combination result as an interaction question worth pursuing. It gives no safe combination for a person taking an anxiety medicine. The membrane review also describes Selank blocking diazepam- and olanzapine-related changes in GABA binding; tissue binding and whole-animal behavior are different observations, so treating them as opposing verdicts would be a mistake.

In a human-serum assay, Selank slowed enzymes that break down enkephalins. Alongside GABA-related activity, that widens the possible interaction questions with medicines affecting mood, pain or alertness.

Immune measurements in people

The small human study in patients with anxiety-asthenic disorders reported a shift in Th1/Th2 cytokine balance and changes in IL-6 expression. Cytokines are signals used by immune cells. This study examined their relative activity in patients who had anxiety with exhaustion.

This is the Selank result I’m least willing to tuck away as a footnote. Calling a compound calming leaves out these immune measurements; calling it an immune booster supplies a verdict the measurements cannot support. The eventual consequences of changing those signals, particularly with immune-modifying medicines or autoimmune conditions, remain uncertain.

The human literature is small, largely Russian and short in duration. Broader replication and longer follow-up could change the picture substantially. I’d like the immune outcomes to receive the same scrutiny as the anxiety outcomes.

Two illustrated technicians examine a glass slide at a microscope in a pale rose workroom — Imagined histology workroom, illustrated for the tissue and immune questions; the people and setting do not represent the study team.

Amidate searches and other labels

The search phrase “Selank 10 mg amidate” combines a compound name, an amount and a modification label. It supplies no study result. The Selank papers cited here cannot establish the identity, purity or effects of material carrying that description, and the amount in the phrase is no instruction for use.

A place or seller name beside “Selank” adds no clinical evidence either. The source list covers the named research compound; it offers no assessment of any commercial source. The comparison page addresses alternative and variant queries within those limits.

Community accounts of reduced worry, easier focus or easier social interaction are anecdotal, not clinical evidence. Reports also include no benefit, tiredness, nasal irritation, headaches and mixed sleep effects. I distrust reassurance assembled from favorable accounts alone. Long-term safety, pregnancy, breastfeeding and combinations with other medicines remain inadequately tested; persistent anxiety merits an assessment by a clinician.